Antisense Oligonucleotide for Spinal Muscular Atrophy
study id #: NCT05187260
condition: Spinal Muscular Atrophy
status: Not yet recruitingpurpose:
This is a longitudinal, multiple-center, observational study of patients genetically confirmed chromosome 5q SMA to monitor the efficacy, safety, tolerability of SPINRAZA® (nusinersen) for up to 24 months.
last updated: February 04, 2022
start date: January 1, 2022
estimated completion: January 31, 2024
last updated: January 11, 2022
size / enrollment: 1000
study description: SPINRAZA® (nusinersen) is an antisense oligonucleotide (ASO) designed to treat SMA caused by mutations in chromosome 5q that lead to SMN protein deficiency. Nusinersen, approved by the FDA for treatment of SMA in 2016, was approved by the Chinese National Medical Products Administration in 2019.
This is a prospective, longitudinal, multi-center, observational study designed to evaluate the efficacy, safety, tolerability and of nusinersen in patients genetically confirmed chromosome 5q SMA in China. Subjects with SMA I/II/III who are planning to initiate treatment with nusinersen will be enrolled in this study. All patients will be treated by their physicians according to standard clinical practice. SPINRAZA® (nusinersen) is administered as an intrathecal injection. A total of 5ml of cerebrospinal fluid (CSF) will be removed prior to administration of SPINRAZA® (nusinersen), which will be collected by the study. Neurofilament light chain (NfL) in CSF and blood will be assessed for the efficacy of nusinersen, as well as motor and pulmonary function.
There will be a total of nine visits. All the patients with 5q SMA receiving nusinersen will be visited face to face at baseline, day 14, day 28 and day 63 after treatment initiation, and then 4-month intervals through month 24/22.
- Change in CSF Neurofilament Light Chain levels since baseline
Measured by Single-molecule Array
- up to 24months
- Change in serum Neurofilament Light Chain levels since baseline
up to 24months
• Eligible Sexes: all
Patients genetically confirmed 5q SMA including types I, II and III, who are planning to initiate treatment with SPINRAZA® (nusinersen) as part of their clinical care plan.
Non-5q SMA patients undergoing clinical standard lumbar puncture
Non-SMA subjects including Asymptomatic carriers of SMA, relatives of SMA patients and carriers, and patients undergoing clinical standard lumbar puncture
Participants or Parent(s)/legal guardian(s) willing and able to complete the informed consent process
exclusion criteria: Criteria:
Contraindication for lumbar puncture
Inability to access intrathecal space for nusinersen injection
Stanford Healthcare – Spinal Muscular AtrophyStanford Neuromuscular Program has exten...
Charlotte Jane Sumner, MDDr. Charlotte Sumner is a Professor of N...
Thomas Crawford, MDDr. Tom Crawford has been a member of th...
Spinal Muscular Atrophy (SMA)Spinal muscular atrophy (SMA) is a genet...
VA Cleveland Amputation SMA Group (Cleveland, OH)Meets every Monday from 2:00 – 3:00 at...
Spinal Muscular Atrophy 2019: SMA Pathophysiology, Diagnosis and Clinical Presentationshttps://www.youtube.com/watch?v=cUuWue8M...
Nusinersen for Spinal Muscular Atrophy in the United States: Findings From a Retrospective Claims Database AnalysisSpinal muscular atrophy (SMA) is a rare,...